Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.04
- Piotroski Score 5.00
- Grade Buy
- Symbol (BVS)
- Company Bioventus Inc.
- Price $12.12
- Changes Percentage (7.73%)
- Change $0.87
- Day Low $11.25
- Day High $12.25
- Year High $12.41
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $12.00
- High Stock Price Target $12.00
- Low Stock Price Target $2.50
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.33
- Trailing P/E Ratio -19.18
- Forward P/E Ratio -19.18
- P/E Growth -19.18
- Net Income $-156,230,000
Income Statement
Quarterly
Annual
Latest News of BVS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Bioventus divested its Advanced Rehabilitation business to enhance focus on core operations. Strong performance in Pain Treatments was driven by sales team execution. Surgical Solutions segment saw gr...
By Yahoo! Finance | 3 days ago -
Bravura Solutions' (ASX:BVS) Returns On Capital Tell Us There Is Reason To Feel Uneasy
Monitoring financial metrics like Return on Capital Employed (ROCE) can indicate if a business is declining. For example, declining ROCE and capital employed can suggest a mature business in decline. ...
By Yahoo! Finance | 3 weeks ago -
Bravura Solutions Limited (ASX:BVS) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Bravura Solutions' stock has surged by 20% recently, but its Return on Equity (ROE) of 6.6% raises concerns about its financial health. The company's low ROE and shrinking earnings compared to industr...
By Yahoo! Finance | 1 month ago
